{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:01:06Z","timestamp":1777680066252,"version":"3.51.4"},"reference-count":48,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Hosp Pharm"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:p>Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy &amp; Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy\/nursing in-services. A comprehensive target drug utilization evaluation\/medication use evaluation (DUE\/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433. The September 2016 monograph topics are barictinib, buprenorphine implants, sarilumab, sofosbuvir\/velpatasvir, and cholera vaccine, live, oral. The Safey MUE is on sofosbuvir\/velpatasvir.<\/jats:p>","DOI":"10.1310\/hpj5108-665","type":"journal-article","created":{"date-parts":[[2016,9,20]],"date-time":"2016-09-20T17:35:52Z","timestamp":1474392952000},"page":"665-686","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Elbasvir\/Grazoprevir"],"prefix":"10.1177","volume":"51","author":[{"given":"Dennis J.","family":"Cada","sequence":"first","affiliation":[{"name":"The Formulary, College of Pharmacy, Washington State University Spokane;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne P.","family":"Kim","sequence":"additional","affiliation":[{"name":"Drug Information Resident, College of Pharmacy, Washington State University Spokane;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danial E.","family":"Baker","sequence":"additional","affiliation":[{"name":"Drug Information Center, and College of Pharmacy, Washington State University Spokane."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2016,8,1]]},"reference":[{"key":"bibr1-hpj5108-665","volume-title":"Xepatier (elbasvir\/grazoprevir) [prescribing information].","year":"2016"},{"key":"bibr2-hpj5108-665","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30974-0"},{"key":"bibr3-hpj5108-665","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30013-1"},{"key":"bibr4-hpj5108-665","doi-asserted-by":"publisher","DOI":"10.7326\/M15-0785"},{"key":"bibr5-hpj5108-665","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(15)34080-4"},{"key":"bibr6-hpj5108-665","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(15)00114-9"},{"key":"bibr7-hpj5108-665","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30015-5"},{"key":"bibr8-hpj5108-665","volume-title":"Harvoni (ledipasvir\/sofosbuvir) [prescribing information].","year":"2016"},{"key":"bibr9-hpj5108-665","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512610"},{"key":"bibr10-hpj5108-665","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512612"},{"key":"bibr11-hpj5108-665","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512614"},{"issue":"9973","key":"bibr12-hpj5108-665","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(14)61793-1","volume":"385","author":"Sulkowski M.","year":"2015","journal-title":"Lancet."},{"issue":"9973","key":"bibr13-hpj5108-665","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(14)61795-5","volume":"385","author":"Lawitz E.","year":"2015","journal-title":"Lancet."},{"key":"bibr14-hpj5108-665","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2014.902049"},{"key":"bibr15-hpj5108-665","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)31113-2"},{"key":"bibr16-hpj5108-665","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2013.06.014"},{"key":"bibr17-hpj5108-665","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00324-12"},{"key":"bibr18-hpj5108-665","unstructured":"LahserF. LiuR. BystolK. A combination containing MK-5172 (HCV NS3 protease inhibitor) and MK-8742 (HCV NS5A inhibitor) demonstrates high barrier to resistance in HCV replicon [abstract]. 2013 International Conference on Viral Hepatitis; March 25\u201326, 2013; New York. http:\/\/www.iapac.org\/icvh\/presentations\/ICVH2013_OA28.pdf. Accessed September 23, 2015."},{"key":"bibr19-hpj5108-665","unstructured":"AASLD\/IDSA\/IAS-USA. HCV guidance: Recommendations for testing, managing, and treating hepatitis C. HCV Guidelines website. http:\/\/www.hcvguidelines.org. Accessed April 1, 2016."},{"key":"bibr20-hpj5108-665","unstructured":"Merck Sharp & Dohme Corp. Study of efficacy and safety of grazoprevir (MK-5172)\/elbasvir (MK-8742) combination regimen for treatment-naive participants with chronic hepatitis C virus genotypes 1, 4, and 6 (MK-5172\u2013060). ClinicalTrials.gov website. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02105467. Updated September 15, 2015. Accessed May 16, 2016. NLM identifier: NCT02105467."},{"key":"bibr21-hpj5108-665","unstructured":"Merck's pivotal phase 3 C-EDGE program evaluating grazoprevir\/elbasvir shows high sustained virologic responses across broad range of patients with chronic hepatitis C virus infection [press release]. Kenilworth, NJ: Merck; April 24, 2015. http:\/\/www.mercknewsroom.com\/news-release\/hepatitis-c-newsroom\/mercks-pivotal-phase-3-c-edge-program-evaluating-grazoprevirelbasv. Accessed July 8, 2015."},{"key":"bibr22-hpj5108-665","unstructured":"Merck Sharp & Dohme Corp. Study of efficacy and safety of grazoprevir (MK-5172) + elbasvir (MK-8742) with or without ribavirin for participants with hepatitis C genotype 1, 4, or 6 infections who have failed prior treatment with pegylated interferon + ribavirin (MK-5172-068). ClinicalTrials.gov website. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02105701. Updated June 29, 2015. Accessed July 9, 2015. NLM identifier: NCT02105701."},{"key":"bibr23-hpj5108-665","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)31089-8"},{"key":"bibr24-hpj5108-665","unstructured":"RockstrohJ.K. NelsonM. KatlamaC. C-EDGE COINFECTION: Phase 3 study of grazoprevir\/elbasvir in patients with HCV\/HIV [abstract]. 50th Annual Meeting of European Association for the Study of the Liver International Liver Congress; April 22\u201326, 2015; Vienna, Austria. Abstract P0887. http:\/\/www.viraled.com\/modules\/info\/files\/files_55491682b2878.pdf. Accessed October 31, 2015."},{"key":"bibr25-hpj5108-665","unstructured":"Merck Sharp & Dohme Corp. An efficacy and safety study of grazoprevir (MK-5172) + elbasvir (MK-8742) in the treatment of chronic hepatitis C virus in participants who are co-infected with human immunodeficiency virus (C-EDGE COINFECTION) (MK-5172\u2013061). ClinicalTrials.gov website. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02105662. Updated February 3, 2016. Accessed May 16, 2016. NLM identifier: NCT02105662."},{"key":"bibr26-hpj5108-665","unstructured":"Merck Sharp & Dohme Corp. Study of efficacy and safety of grazoprevir (MK-5172) + elbasvir (MK-8742) in chronic hepatitis C participants with Child-Pugh (CP)-B hepatic insufficiency (MK-5172-059). ClinicalTrials.gov website. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02115321. Updated February 19, 2016. Accessed May 16, 2016. NLM identifier: NCT02115321."},{"key":"bibr27-hpj5108-665","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30156-2"},{"key":"bibr28-hpj5108-665","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00349-9"},{"key":"bibr29-hpj5108-665","doi-asserted-by":"crossref","unstructured":"RothD. NelsonD. BruchfeldA. C-SURFER: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease [abstract]. 50th Annual Meeting of European Association for the Study of the Liver International Liver Congress; April 22\u201326, 2015; Vienna, Austria. Abstract LP02. http:\/\/www.viraled.com\/modules\/info\/files\/files_5551223719445.pdf. Accessed November 1, 2015.","DOI":"10.1016\/S0168-8278(15)30156-2"},{"issue":"3","key":"bibr30-hpj5108-665","first-page":"iiil56","volume":"30","author":"Bruchfeld A.","year":"2015","journal-title":"Nephrol Dial Transplant."},{"key":"bibr31-hpj5108-665","unstructured":"Merck Sharp & Dohme Corp. Safety and efficacy of grazoprevir (MK-5172) + elbasvir (MK-8742) in participants with chronic hepatitis C and chronic kidney disease (MK-5172-052) (C-SURFER). ClinicalTrials.gov website. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02092350. Updated March 14, 2016. Accessed May 16, 2016. NLM identifier: NCT02092350."},{"key":"bibr32-hpj5108-665","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.04.009"},{"key":"bibr33-hpj5108-665","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ722"},{"key":"bibr34-hpj5108-665","unstructured":"Merck Sharp & Dohme Corp. Study of grazoprevir (MK-5172) + elbasvir (MK-8742) + ribavirin in participants with chronic hepatitis C who failed prior direct-acting antiviral therapy (MK-5172-048). ClinicalTrials.gov website. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02105454. Updated June 3, 2015. Accessed July 9, 2015. NLM identifier: NCT02105454."},{"key":"bibr35-hpj5108-665","unstructured":"Merck Sharp & Dohme Corp. A study of the combination regimen grazoprevir (MK-5172) and elbasvir (MK-8742) \u00b1 ribavirin in participants with chronic hepatitis C (MK-5172-035) (C-WORTHY). ClinicalTrials.gov website. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01717326. Updated May 15, 2015. Accessed July 9, 2015. NLM identifier: NCT01717326."},{"key":"bibr36-hpj5108-665","unstructured":"Merck Sharp & Dohme Corp. Efficacy and safety of combination grazoprevir (MK-5172) + elbasvir (MK-8742) + ribavirin (RBV) in genotype 2 hepatitis C infection (MK-5172-047). ClinicalTrials.gov website. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01932762. Updated April 9, 2015. Accessed July 9, 2015. NLM identifier: NCT01932762."},{"issue":"6","key":"bibr37-hpj5108-665","first-page":"1286A","volume":"60","author":"Lawitz E.","year":"2014","journal-title":"Hepatology."},{"key":"bibr38-hpj5108-665","unstructured":"Merck Sharp & Dohme Corp. Efficacy and safety of grazoprevir (MK-5172), elbasvir (MK-8742), and sofosbuvir for chronic infection with hepatitis C virus genotypes 1 and 3 (MK-5172-074). ClinicalTrials.gov website. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02133131. Updated February 8, 2016. Accessed May 16, 2016. NLM identifier: NCT02133131."},{"key":"bibr39-hpj5108-665","volume-title":"Copegus (ribavirin) [prescribing information].","year":"2015"},{"issue":"4","key":"bibr40-hpj5108-665","first-page":"442A","volume":"58","author":"Caro L.","year":"2013","journal-title":"Hepatology."},{"issue":"4","key":"bibr41-hpj5108-665","first-page":"445A","volume":"58","author":"Talaty J.E.","year":"2013","journal-title":"Hepatology."},{"issue":"4","key":"bibr42-hpj5108-665","first-page":"437A","volume":"58","author":"Caro L.","year":"2013","journal-title":"Hepatology."},{"key":"bibr43-hpj5108-665","doi-asserted-by":"publisher","DOI":"10.1177\/1060028015581848"},{"issue":"4","key":"bibr44-hpj5108-665","first-page":"446A","volume":"58","author":"Caro L.","year":"2013","journal-title":"Hepatology."},{"issue":"4","key":"bibr45-hpj5108-665","first-page":"438A","volume":"58","author":"Yeh W.W.","year":"2013","journal-title":"Hepatology."},{"issue":"4","key":"bibr46-hpj5108-665","first-page":"430A","volume":"58","author":"Yeh W.W.","year":"2013","journal-title":"Hepatology."},{"key":"bibr47-hpj5108-665","unstructured":"FDA approves Zepatier for treatment of chronic hepatitis C genotypes 1 and 4. US Food and Drug Administration website. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm483828.htm. Published January 28, 2016. Accessed March 18, 2016."},{"key":"bibr48-hpj5108-665","unstructured":"CoxE.M. NDA approval letter:\n                      Zepatier\n                      (elbasvir\/grazoprevir NDA 208261). US Food and Drug Administration website. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2016\/208261Orig1s000ltr.pdf. Published January 28, 2016. Accessed March 18, 2016."}],"container-title":["Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1310\/hpj5108-665","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1310\/hpj5108-665","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1310\/hpj5108-665","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:34:22Z","timestamp":1777451662000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1310\/hpj5108-665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,1]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1310\/hpj5108-665"],"URL":"https:\/\/doi.org\/10.1310\/hpj5108-665","relation":{},"ISSN":["0018-5787","1945-1253"],"issn-type":[{"value":"0018-5787","type":"print"},{"value":"1945-1253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,1]]}}}